SEC and Kiromic set­tle over biotech's fail­ure to dis­close clin­i­cal tri­al holds ahead of stock of­fer­ing

The SEC said Tues­day that it set­tled charges filed against Kiromic Bio­Phar­ma, a tiny im­muno-on­col­o­gy start­up based in Texas, for fail­ing to dis­close clin­i­cal holds …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER